Impact of Primary Language on Treatment and Outcomes in Inflammatory Bowel Disease
NCT ID: NCT06405503
Last Updated: 2024-05-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
206 participants
OBSERVATIONAL
2024-06-01
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study aims to determine the impact of primary language on the selection of treatment for IBD and on disease outcomes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Improving OutcoMes in the Pediatric to Adult Care Transition in Inflammatory Bowel Disease
NCT02085083
Medication Adherence in Patients With Inflammatory Bowel Disease (IBD)
NCT02620514
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
NCT02316678
Renal and Urinary Manifestations of Chronic Inflammatory Bowel Diseases.
NCT06814392
A Qualitative Study on Patients' (un)Ability and (un)Willingness to Use Telemonitoring in Inflammatory Bowel Diseases
NCT06123052
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
English as primary language
NO INTERVENTION
NO INTERVENTION - OBSERVATIONAL ONLY
Non-English as primary language
NO INTERVENTION
NO INTERVENTION - OBSERVATIONAL ONLY
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NO INTERVENTION
NO INTERVENTION - OBSERVATIONAL ONLY
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of IBD (CD, UC or indeterminate colitis)
* Willing to provide consent for participation
* Managed at an outpatient clinic either the Yale New Haven Hospital system or the University of Texas at Austin Hospital system.
Exclusion Criteria
* No confirmed diagnosis of IBD
* Not planning to continue care at either study site (i.e. presenting for a consultation only)
* Unwilling to provide signed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Yale University
OTHER
University of Texas at Austin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Linda Anne Feagins, MD
Associate Professor of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dell Medical School at the University of Texas at Austin
Austin, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Linda A Feagins, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY00004331
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.